Friday, April 30, 2021

C.H. Robinson Recognized as a Challenger in the 2021 Gartner Magic Quadrant for Real-Time Transportation Visibility Platforms

  Positioning based on Navisphere Vision’s completeness of vision and ability to execute



EDEN PRAIRIE, Minn. -Thursday 29 April 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Global logistics company C.H. Robinson announced its recognition as a Challenger in the new Gartner Magic Quadrant for Real-Time Transportation Visibility Platforms* (RTTVP). Faced with multiple disruptions from the global pandemic, trade and tariff disputes, severe weather, capacity shortages, and a trade lane blockage, shippers are prioritizing and investing in RTTVP solutions like C.H. Robinson’s Navisphere Vision to improve their resiliency, connectivity, and performance.

Gartner, the world’s leading research and advisory company that publishes the annual series of market data known as Magic Quadrant, reports “the RTTVP market doubled in size in North American in 2020. This growth was accelerated due to the supply chain disruptions created by the pandemic.”

Navisphere Vision, delivered by TMC, a division of C.H. Robinson, helps shippers track, monitor, and respond to supply chain disruptions on a global scale. As a software-as-a-service (SaaS) platform, Navisphere Vision connects and pulls data from shippers’ third-party providers, carriers, and suppliers—plus weather, traffic, and geopolitical monitoring sources—to deliver real-time visibility and insights to inventory at-rest or in-motion, across all modes and regions. With Navisphere Vision’s Internet of Things (IoT) device integrations, customers can monitor and immediately mitigate issues when shipments are impacted by shock, tilt, humidity, light, temperature, or pressure.

“Several major events over the past year have emphasized the vital importance of supply chains, but also highlighted their fragility in some cases,” said Jordan Kass, president of TMC. “The companies who will excel in the years to come will be those with real-time visibility into their supply chains. The ability to consume, combine and analyze data from growing number of integrations and data points will be essential for building a resilient, competitive, and profitable supply chain.”

C.H. Robinson (TMC) was also recognized as a Challenger in the 2021 Gartner Magic Quadrant for Transportation Management Systems.

“We believe these recognitions reinforce the power of our innovative technology, built by and for supply chain experts, backed by the experience and scale of one of the world’s most-connected platforms,” said Kass.

To expand on these capabilities, the company previously announced a commitment to invest $1 billion in technology over the next five years, doubling its previous investment.

A complimentary copy of the Magic Quadrant for Real-Time Transportation Visibility Platforms is available here.

* Gartner, Magic Quadrant for Real-Time Transportation Visibility Platforms, Bart De Muynck, Carly West, 14 April 2021

Gartner Disclaimer

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advice technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About C.H. Robinson

C.H. Robinson solves logistics problems for companies across the globe and across industries, from the simple to the most complex. With $21 billion in freight under management and 19 million shipments annually, we are one of the world’s largest logistics platforms. Our global suite of services accelerates trade to seamlessly deliver the products and goods that drive the world’s economy. With the combination of our multi-modal transportation management system and expertise, we use our information advantage to deliver smarter solutions for our more than 105,000 customers and 73,000 contract carriers. Our technology is built by and for supply chain experts to bring faster, more meaningful improvements to our customers’ businesses. As a responsible global citizen, we are also proud to contribute millions of dollars to support causes that matter to our company, our Foundation and our employees. For more information, visit www.chrobinson.com (Nasdaq: CHRW).

About TMC, a division of C.H. Robinson

Global supply chains are growing increasingly complex. Businesses need the latest technology and industry expertise to advance and stay ahead of the competition. At TMC, a division of C.H. Robinson, we understand what makes supply chains faster, stronger, and more efficient. As a leader in global logistics management, we combine industry expertise with our global technology platform, Navisphere®, to support the world’s most complex supply chains. Our logistics experts are located in Control Tower® locations around the world: Amsterdam, Chicago, Monterrey, São Paulo, Seattle, Shanghai, and Wrocław. This Control Tower® network, supported by our technology platform, connects our customers to their suppliers and supply chain partners. Our customers leverage these capabilities to manage their logistics in over 170 countries across all modes of transportation. For more information, visit www.mytmc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005194/en/

Contacts

Kylie Crull
612-719-1723
kylie.crull@chrobinson.com


Permalink : https://www.aetoswire.com/news/ch-robinson-recognized-as-a-challenger-in-the-2021-gartner-magic-quadrant-for-real-time-transportation-visibility-platforms/en

Takeda Manufacturing Facilities in Japan and Ireland Recognized With Category Awards for 2021 Facilities of the Year

 OSAKA, Japan-Thursday 29 April 2021 [ AETOS Wire ]

Both Awards, Issued by the International Society for Pharmaceutical Engineering (ISPE), Underscore Takeda’s Leadership in Digital and Innovative Technologies
New Solid Pharmaceutical Packaging Building With Automatic Line Clearance in Hikari, Japan, Wins Process Intelligence and Innovation Award
End-to-End High Potent Drug Facility in Grange Castle, Ireland, Is Recognized as Category Winner for Facility Integration
 

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories. Takeda’s new solid pharmaceutical packaging building in Hikari, Japan, was recognized with the 2021 “Process Intelligence and Innovation” category award. Additionally, the end-to-end high potent drug facility in Grange Castle, Ireland, was selected as “Facility Integration” category winner.

“I am honored that Takeda receives two awards for the production and packaging of small molecule solid dosage form products,” said Thomas Wozniewski, global manufacturing & supply officer of Takeda. “In 2018, the Los Angeles plasma facility received two FOYA awards, now, two of our sites in Japan and in Europe got awarded in the categories ‘Process intelligence and innovation’ as well as ‘Facility integration’. This illustrates that Takeda is constantly investing into state of the art facilities applying best in class process as well as digital standards. Both projects in Hikari and in Grange Castle also demonstrate that significant technology improvements for small molecule modalities are still achievable, both in a cost as well as in a time efficient manner.”

Takeda’s Hikari plant is located in the south of Japan in the Yamaguchi prefecture. One of Takeda`s largest plants, it features advanced production systems for active pharmaceutical ingredients (API), drug formulation, biological products, and others offering a stable supply of high-quality pharmaceutical products throughout the world. The project at the Hikari site is a four-story building designed to elevate pharmaceutical packaging operations to a new industrial standard. The facility features highly automated end-to-end packaging equipment, including “end of line” case packers, automated guided vehicles (AGVs) and robots to feed the automated storage and retrieval system (ASRS). Additionally, the site developed and introduced an automatic line clearance system (ALC) with 360° cameras and laser sensors utilizing artificial intelligence (AI) to help significantly increase efficiency in the pharmaceutical packaging process. Takeda’s Hikari plant exemplifies how novel application of commercially available and custom developed process manufacturing tools leads to superior results and advanced process understanding.

The Grange Castle site in Ireland is located in the Dublin area, and it includes three manufacturing facilities. The production facility which now got awarded by the ISPE is a standalone, high containment, cutting-edge production facility dedicated to manufacturing Takeda’s treatment for multiple myeloma. The application of good design practices and superior conceptual planning led to the excellent integration of facility and process. The innovative design as an ‘all-in-one’ facility incorporates the entire end-to-end production process from active pharmaceutical ingredients to drug product and packaging under one roof. This significantly simplifies the supply chain for one of Takeda´s global oncology products to ensure unconstrained availability to patients worldwide.

“The design teams have implemented best-in-class digital technologies to guarantee the facilities use the latest developments in paperless automation, robotics and augmented reality. This strategic use of digital and automated systems has led to a state-of-the-art facility design that positions Takeda as a frontrunner in our industry,” added Gunter Baumgartner, head of Global Engineering at Takeda.

An official ceremony of all winning projects and awards is planned at this year’s ISPE Annual Meeting & Expo in Boston, MA, in November.

About the ISPE Facility of the Year Awards Program
Established in 2004, the Facility of the Year Awards (FOYA) recognizes state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operations, while sharing the development of new applications of technology and cutting-edge approaches. For more information, visit https://ispe.org/facility-year-awards.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005099/en/

Contacts
Japanese Media
Ryoko Matsumoto
ryoko.matsumoto@takeda.com
+81 (0) 3-3278-3414

Irish Media
Freeha Rafiq
freeha.rafiq@takeda.com
+44 (0) 7500953471

Other Media
Holly Campbell
holly.campbell@takeda.com
+1 617-588-9013



Permalink : https://www.aetoswire.com/news/takeda-manufacturing-facilities-in-japan-and-ireland-recognized-with-category-awards-for-2021-facilities-of-the-year/en


Tigo Dismisses Patent Infringement Lawsuit as Tigo and APsystems Sign License Agreement

 Settlement validates Tigo IP while reinforcing customer choice in the marketplace


CAMPBELL, Calif.-Thursday 29 April 2021 [ AETOS Wire ]


(BUSINESS WIRE)-- Tigo Energy, Inc., the solar industry worldwide leader in Flex-MLPE (Module Level Power Electronics), announced that it has reached a settlement with Altenergy Power Systems (“APsystems”) over a lawsuit regarding the infringement of Tigo’s intellectual property by APsystems. As part of the settlement, APsystems obtain a license to use Tigo’s rapid shutdown technology.


“Ultimately, we believe this arrangement is a win for PV customers everywhere,” stated Zvi Alon, Chairman and CEO of Tigo. “I want to thank APsystems for recognizing our intellectual property and arriving at an outcome that works for all parties involved.”


Tigo endorses the need to provide customers alternative solutions and will cooperate with APsystems to continue the development of leading edge solutions. Tigo’s complaint included six patents related to various systems and methods used in the PV module rapid shutdown unit applicable to both the Rapid Shutdown device as well as the Rapid Shutdown transmitter. These are the same patents that Tigo disclosed to the Sunspec Alliance in 2017.


Terms of the license agreement are not disclosed and include APsystems legal entities in the US as well as in China. Inquiries are welcome and can be sent to marketing@tigoenergy.com.


About Tigo


Tigo is the worldwide leader in flexible module level power electronics (MLPE) with innovative solutions that significantly increase energy production, decrease operating costs, and enhance safety of photovoltaic (PV) systems. Tigo’s TS4 platform maximizes the benefit of PV systems and provides customers with the most scalable, versatile, and reliable MLPE solution available. Tigo was founded in Silicon Valley in 2007 to accelerate the adoption of solar energy worldwide. Tigo systems operate on 7 continents and produce gigawatt hours of reliable, clean, affordable and safe solar energy daily. Tigo's global team is dedicated to making the best MLPE on earth so more people can enjoy the benefits of solar. Visit us at www.tigoenergy.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005367/en/


Contacts

John Lerch

408.402.0802 x430

marketing@tigoenergy.com



Permalink : https://www.aetoswire.com/news/tigo-dismisses-patent-infringement-lawsuit-as-tigo-and-apsystems-sign-license-agreement/en


Hikma and Melinta Therapeutics sign exclusive licensing agreement for two novel anti-infectives for the Middle East and North Africa region

 London, United Kingdom-Thursday 29 April 2021 [ AETOS Wire ]


Hikma Pharmaceuticals PLC (Hikma) and Melinta Therapeutics (Melinta) today announced they have entered into an exclusive licensing agreement for Vabomere® (meropenem and vaborbactam) and Orbactiv® (oritavancin), two novel anti-infective injectable products, for the Middle East and North Africa (MENA) region.


In the United States, Orbactiv® is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections due to designated susceptible Gram-positive pathogens and Vabomere® is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections, including pyelonephritis, caused by designated susceptible Gram-negative pathogens.


Under the terms of the agreement, Hikma is responsible for the registration and commercialisation of these two products across its 18 MENA markets. This extends Hikma’s existing partnership with Melinta for their intravenous and oral formulations of Baxdela® (delafloxacin), a novel antibiotic product. The addition of these two innovative products to Hikma’s portfolio builds on its hospital anti-infective franchise and provides healthcare professionals with more treatment options.


“We are excited to be extending our partnership with Melinta and bring Vabomere® and Orbactiv® to our patients in MENA,” said Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA. “As one of the leading suppliers in the region, it is our responsibility to equip doctors with the latest and most innovative developments to treat their patients. This agreement supports our strategy of establishing a global network of partners to strengthen our portfolio and improve availability of treatment options in the MENA region.”


“Hikma shares our commitment to ensure that all patients who need our life-saving therapies can get them,” said Christine Ann Miller, President and Chief Executive Officer of Melinta. “We’re thrilled to extend our partnership to reach patients in need in the MENA region with Vabomere® and Orbactiv®.”


Contacts

Hikma Pharmaceuticals PLC


Susan Ringdal


EVP, Strategic Planning and Global Affairs    


+44 (0)20 7399 2760/ +44 7776 477050


uk-investors@hikma.uk.com


 


Dana Alhusseini


Communication Manager        


+962 6 580 2900


Dalhusseini@hikma.com 


Melinta Therapeutics


Susan Blum


Interim Chief Financial Officer


+1 312 767 0296


info@melinta.com




Permalink : https://www.aetoswire.com/news/hikma-and-melinta-therapeutics-sign-exclusive-licensing-agreement-for-two-novel-anti-infectives-for-the-middle-east-and-north-africa-region/en



Thursday, April 29, 2021

NielsenIQ and J.D. Power Enter Strategic Alliance to Bring Unparalleled Automotive Research to Major Growth Markets

 Data-driven insights will inform automotive sector recovery post COVID-19


SINGAPORE-Thursday 29 April 2021 [ AETOS Wire ]


(BUSINESS WIRE)-- NielsenIQ, an industry leader in global measurement, and J.D. Power, a global leader in data analytics and consumer intelligence, today announced their intent to launch a multinational strategic alliance to bring benchmark automotive customer experience studies and deep auto industry data analysis to major growth markets such as India, Southeast Asia and the Middle East.


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210418005017/en/


Drawing on the strong market presence of NielsenIQ and the deep industry expertise of J.D. Power, the alliance will feature J.D. Power benchmark automotive studies, recognized as the gold standard in the automotive industry, complemented by NielsenIQ’s new digital and technology-based platforms and value-added services like social listening analysis.


Combining NielsenIQ and J.D. Power capabilities will allow automotive sector clients to strategize for the future based on data-driven tools and insights. As the global economy recovers from the pandemic, data-driven decision-making will become more important than ever before. Access to accurate data, analytics and trends in consumer behavior will help decision-makers understand consumers’ wants and needs, and produce vehicles that are proven to be in demand.


“In today’s agile world, a key vision of NielsenIQ is to create the best alliances that deliver an unmatched value proposition to clients by combining our unique offerings with the best the external world has to offer,” said Prasun Basu, Global Head, Strategic Alliances and New Verticals. “We are thrilled that NielsenIQ and J.D. Power, two best-in-class trusted global leaders, have come together to offer that outstanding combination of client advisory and market understanding with expertise in the automotive sector through syndication.”


“J.D. Power data, analytics and benchmark studies are the industry standard for much of the world, and this alliance will allow global OEMs to use one structure for benchmarking and apply it to all the markets where they operate,” said Doug Betts, President of Global Automotive at J.D. Power. “This will drive efficiency to the structure and organization for improvement of product and service for their customers. NielsenIQ’s strong presence makes it the best possible teammate to bring this service into these markets.”


The NielsenIQ Consumer Insights team, led by Joe Ellis, Global Head of the Automotive, Tech, Telco and Finance verticals, will manage in-market activities, including sales, servicing, data collection and quality control. The integration of NielsenIQ’s local presence, impeccable servicing, and robust on the ground processes with the ingenuity of J.D. Power’s global approach of benchmarking automotive quality, service and sales will provide transformative data and insights to future-proof clients.


ABOUT NIELSENIQ


NielsenIQ is the leader in providing the most complete, unbiased view of consumer behavior, globally. Powered by a ground-breaking consumer data platform and fueled by rich analytic capabilities, NielsenIQ enables bold, confident decision-making for the world’s leading consumer goods companies and retailers.


Using comprehensive data sets and measuring all transactions equally, NielsenIQ gives clients a forward-looking view into consumer behavior in order to optimize performance across all retail platforms. Our open philosophy on data integration enables the most influential consumer data sets on the planet. NielsenIQ delivers the complete truth.


NielsenIQ, an Advent International portfolio company, has operations in nearly 100 markets, covering more than 90% of the world’s population. For more information, visit www.nielseniq.com


ABOUT J.D. POWER


J.D. Power is a global leader in consumer insights, advisory services and data and analytics. A pioneer in the use of big data, artificial intelligence (AI) and algorithmic modeling capabilities to understand consumer behavior, J.D. Power has been delivering incisive industry intelligence on customer interactions with brands and products for more than 50 years. The world's leading businesses across major industries rely on J.D. Power to guide their customer-facing strategies.


J.D. Power is headquartered in Troy, Mich., and has offices in North America, Europe and Asia Pacific. To learn more about the company’s business offerings, visit JDPower.com/business.


View source version on businesswire.com: https://www.businesswire.com/news/home/20210418005017/en/

Contacts


Media Relations

Gillian Mosher, gillian.mosher@nielseniq.com, +1-647-282-9714

Melina Mammidou, melina.mammidou@nielseniq.com, +357-99422160

Geno Effler, media.relations@jdpa.com, +1-714-621-6224


Permalink : https://www.aetoswire.com/news/nielseniq-and-jd-power-enter-strategic-alliance-to-bring-unparalleled-automotive-research-to-major-growth-markets/en 

ZeroFOX Embraces Partner-First Strategy to Further Accelerate Rapid Growth, Launches New Global Partner Program

 External Threat Intelligence and Protection leader strengthens commitment to partner ecosystem, accelerating new capabilities and benefits


BALTIMORE-Thursday 29 April 2021 [ AETOS Wire ]


(BUSINESS WIRE)-- ZeroFOX, leader in External Threat Intelligence and Protection, today announced the launch of the ZeroFOX Global Partner Program, a strategic pivot to a partner-first strategy. This move significantly increases ZeroFOX’s investment in partner enablement and commitment to conducting all business with and through their full partner ecosystem.


Another leap forward following the company’s significant expansion of cyber threat intelligence capabilities and addition of three 24/7 global security operations centers (SOCs), ZeroFOX’s partner-first strategy will accelerate capabilities for new and existing customers. Supported by a three-tier structure with escalating benefits, including graduating sales incentives, white glove support and marketing development funds, the Global Partner Program also offers a comprehensive go-to-market toolbox to meet the on-demand needs of a global salesforce. Specialized, entrepreneurial partner organizations with access to strategic geographic and vertical markets will be supported through an incubator program that incentivizes successful marketing initiatives, achieving training goals and overall business velocity.


Gartner forecasts that worldwide IT spending will increase 6.2% this year compared to last, reaching $3.9 trillion. Amid this tech growth, businesses are re-examining their cybersecurity approach. In fact, over half (55%) of tech and security executives plan to increase their cyber budgets this year, according to a recent PwC survey. With remote work and digital dependency – including an influx in social media use driven by the pandemic – contributing directly to this rise in attacks, it’s essential that the cybersecurity industry works to drive resiliency across markets.


“Our partners rely on ZeroFOX’s unmatched pace of innovation and commitment to delivering the world’s strongest external threat intelligence service. Together, we have put ourselves in a position to deliver unrivaled protection, intelligence, and disruption capabilities to all of our customers,” said James C. Foster, CEO of ZeroFOX. “Furthermore, our customers appreciate that as a partner-first organization, we invest in differentiated partner solutions. Our AI platform is a true difference maker for our partners and customers alike.”


With ZeroFOX’s Global Partner Program, partners and MSSPs seeking to increase customer value will be provided a rich set of professional services capabilities that ultimately enrich their core offering. To lead the charge, ZeroFOX has hired a full global partnerships team of channel veterans, including a dedicated team of channel partner directors, solution engineers and marketing experts, led by ZeroFOX Vice President of Global Partnerships, Brian Costello.


“ZeroFOX’s investment in enabling partners through sales, marketing, and technical expertise means that our partners can go-to-market faster, drive more demand, and secure more sustainable sources of revenue,” said Brian Costello, Vice President of Global Partnerships at ZeroFOX. “Both on-demand and white glove programs mean partners can confidently project the value that ZeroFOX brings to their portfolio.”


ZeroFOX expects to double partner contribution to the business this year, already acquiring the company’s largest customer in company history through a partner-based contract. Partners continue to broaden ZeroFOX’s capabilities into several verticals targeted widely by cyber criminals, including healthcare and financial services, and extend the company’s geographic footprint and expansion in EMEA, APAC and LATAM.


“ZeroFOX’s ability to bridge social, mobile, surface, and deep and dark web environments delivers a powerful digital risk protection solution in line with Exclusive Networks UK’s ethos of enabling our Partners to differentiate themselves through innovation and addressing the new challenges faced by end users,” said Mark Parr, Director of Strategic Vendors at Exclusive Networks UK. “Our partnership with ZeroFOX has helped drive growth and uncover new opportunities alongside our diverse range of partners. Furthermore, ZeroFOX's integrations with several of our existing technologies results in the creation of comprehensive and scalable solutions to be adopted by our broad partner base. The synergy between Exclusive Networks UK and ZeroFOX extends beyond technology with both organizations leading with a ‘can do’ approach and continually striving to innovate. This makes working together a natural choice.”


To find out more information about ZeroFOX, please visit our website at www.zerofox.com.


About ZeroFOX – ZeroFOX provides enterprises protection, intelligence and disruption to dismantle external threats to brands, people, assets and data across the public attack surface in one, comprehensive platform. With complete global coverage across the surface, deep and dark web and an Intel-backed artificial intelligence-based analysis engine, the ZeroFOX Platform identifies and remediates targeted phishing attacks, credential compromise, data exfiltration, brand hijacking, executive and location threats and more. The patented ZeroFOX Platform technology processes and protects millions of posts, messages and accounts daily across the social and digital landscape, spanning LinkedIn, Facebook, Slack, Instagram, Pastebin, YouTube, mobile app stores, domains, cloud-based email and more.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005428/en/


Contacts

ZeroFOX

Contact Press at ZeroFOX


PAN Communications

Kristen Hyle

401-219-9494

ZeroFOX@pancomm.com



Permalink : https://www.aetoswire.com/news/zerofox-embraces-partner-first-strategy-to-further-accelerate-rapid-growth-launches-new-global-partner-program/en


First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment

ST. GALLEN, Switzerland -Wednesday 28 April 2021 [ AETOS Wire ]

  •     CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US
  •     CARE-HK in HF is designed to evaluate the use of Veltassa® in enabling patients to remain on RAASi therapy in HF patients with or at high risk for HK
  •     Topline results are anticipated in 2024

(BUSINESS WIRE)-- Regulatory News:

Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high risk for HK). This non-interventional clinical study aims to better understand renin-angiotensin-aldosterone system inhibitors (RAASi) treatment decisions in clinical practice, potential barriers to achieving optimal guideline-directed care in HF patients with or at high risk for HK, and to assess how Veltassa® may be used in the management of this patient population.

“One of the most pressing issues in management of chronic heart failure is that therapies that have proven to reduce the risk of death and hospitalizations, and are thus strongly recommended by the guidelines, are not optimally used in clinical practice. This is certainly the case with RAASi, which are under-used in many patients, especially those with or at high risk of hyperkalemia,” said Dr. Mikhail Kosiborod, cardiologist at Saint Luke’s Mid America Heart Institute, Vice President of Research at Saint Luke’s Health System and Professor of Medicine at University of Missouri-Kansas City. “CARE-HK in HF will investigate the patterns of RAASi use, and barriers to treatment optimization, and examine whether adherence to guidelines is associated with improved real-world outcomes. This data from a large, international, prospective registry – the first of its kind to focus on this vulnerable patient group – will be very useful in future efforts to optimize the quality of care.”

Dr. Stefan Anker, Professor at Charité Universitätsmedizin, Berlin, Germany, added: “Hyperkalemia is frequent in HF patients and when a patient experienced it for the first time, there is a high likelihood to experience it again. Hyperkalemia is too rarely managed effectively. Taking care of hyperkalemia chronically may be the key to increase our ability to treat more patients with guideline recommended therapies such as RAASi and MRAs to meet the therapeutic goals. By learning from the CARE-HK in HF registry about the RAASi treatment patterns and the management of hyperkalemia, we may improve the current clinical practice for our HF patients with or at high risk of HK.”

Dr. Klaus Henning Jensen, Chief Medical Officer Vifor Pharma commented: “I am very pleased about the enrollment of the first patient in the CARE-HK in HF registry, which to date is the most important commitment in real-world evidence to evaluate RAASi therapy in combination with the use of Veltassa®. CARE-HK in HF will help the medical community to better understand the potential value of Veltassa® in treating hyperkalemia. We are looking forward to quickly ramping up enrollment to meet interest from participating hospitals and physicians.”

About CARE-HK in HF
This non-interventional, international, multi-center registry includes approximately 5,000 patients in 11 countries and 185 sites in Europe and the US. As a primary objective, CARE-HK in HF sets out to describe RAASi treatment patterns, specifically in the context of HK management, and to evaluate the potential role of Veltassa® in HF patients using RAASi therapy in clinical practice by comparing patients treated and not treated with Veltassa®. Patients with chronic heart failure diagnosed at least three months prior to enrollment and with or at greater risk of HK are eligible. They will be receiving renin-angiotensin-aldosterone system inhibitors and either receiving, or be candidates for, mineralocorticoid receptor antagonist (MRA) treatment per a relevant treatment guideline. Data will be collected two years retrospectively or from the onset of HF, and each patient will follow routine clinical care prospectively for two to four years. First results on the baseline data and retrospective analyses are expected in 2022, with topline results anticipated for 2024.

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.

About Veltassa®
Veltassa® is a sodium-free potassium binder approved for the treatment of hyperkalaemia. Veltassa® should not replace emergency treatment for life-threatening hyperkalaemia. Made in powder form consisting of smooth, spherical beads, Veltassa® is mixed with water and taken once a day with food. Veltassa® is not absorbed and acts within the gastrointestinal tract. It binds to potassium in exchange for calcium, primarily in the colon. The potassium is then excreted from the body through the normal excretion process.

About hyperkalemia
HK can cause life-threatening abnormal heart rhythm and even sudden death1. There are often no warning symptoms, meaning patients can unknowingly experience recurring spikes in potassium levels and be at risk of cardiac events.

References:

1 Desai AS, et al. J Am Coll Cardiol 2007;50:1959–66.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005946/en/
Contacts

Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com

Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com

Permalink : https://www.aetoswire.com/news/first-patient-enrolled-in-care-hk-in-hf-to-evaluate-role-of-veltassareg-patiromer-in-enabling-raasi-treatment/en